Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

October 29, 2019

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the driving force behind biosimilar use in oncology.

October 28, 2019

MCLA-128, an investigational bispecific HER2/HER3 antibody, demonstrated radiological and clinical responses in patients with metastatic pancreatic ductal adenocarcinoma and metastatic non–small cell lung cancer who have NRG1 fusions.

October 25, 2019

Eileen M. O’Reilly, MD, discusses emerging strategies in pancreatic cancer.

October 25, 2019

Daniela Molena, MD, discusses the role of screening and the implementation of minimally invasive surgical techniques in early-stage lung cancer.

October 24, 2019

Daniela Molena, MD, discusses factors that determine if a patient with non–small cell lung cancer is eligible for surgical resection.

October 23, 2019

Mark G. Kris, MD, discusses the impact biosimilars for bevacizumab (Avastin) could have in lung cancer.

October 23, 2019

David H. Ilson, MD, PhD, discusses current treatment options for patients with gastric cancer, the challenges with the KEYNOTE-062 trial, and other immunotherapy agents coming down the pipeline.

October 22, 2019

Isabel Preeshagul, DO, MBS, discusses the need for more information about using biosimilars when treating patients with cancer.

October 22, 2019

Michael D. Offin, MD, discusses the potential implications of introducing biosimilars into the field of oncology.

October 22, 2019

Anthony R. Mato, MD, MSCE, discusses the current immunotherapy options for patients with chronic lymphocytic leukemia.

October 18, 2019

Andrew D. Zelenetz, MD, PhD, discusses research with zanubrutinib in mantle cell lymphoma.

October 17, 2019

Anthony R. Mato, MD, MSCE, discusses the use of biosimilars in chronic lymphocytic leukemia.

October 16, 2019

Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the phase II ENTRATA trial in advanced renal cell carcinoma (RCC).

October 15, 2019

Anthony R. Mato, MD, MSCE, discusses where CAR T cell-therapy will fit into the treatment paradigm of chronic lymphocytic leukemia.

October 11, 2019

Eileen O'Reilly, MD, discusses the phase II NEOLAP study which showed that more patients with locally advanced pancreatic cancer were able to undergo surgical resection following induction chemotherapy with gemcitabine and nab-paclitaxel or sequential FOLFIRINOX.

October 09, 2019

Patients with neuroendocrine tumors that have metastasized to the liver derive clinical benefit from locoregional therapies, but treatment guidelines for employing these strategies must be more fully developed.

October 08, 2019

Eileen O'Reilly, MD, associate director for clinical research and medical oncologist at Memorial Sloan Kettering Cancer Center, discusses agents in development in advanced pancreatic cancer.

September 27, 2019

David H. Ilson, MD, PhD, discusses the utility of TAS-102 in gastric and GEJ adenocarcinoma as well as other encouraging research in these spaces.

September 25, 2019

Andrew D. Zelenetz, MD, PhD, discusses approved treatment options for patients with mantle cell lymphoma, as well as treatments coming down the pipeline.

September 20, 2019

Serial assessment of blood-based immune markers showed that the risk of progression from monoclonal gammopathy of undetermined significance, the precursor disease to multiple myeloma is fluctuating rather than determinate, and these patients can experience progression to myeloma within 5 years.